Telehealth providers will soon offer more affordable access to weight loss drug Wegovy, according to manufacturer Novo ...

Hims & Hers ( HIMS) stock popped more than 20% in trading early Tuesday after Novo Nordisk ( NVO) announced a partnership with it and other telehealth platforms to offer patients access to the ...

Deals with Hims & Hers, LifeMD and Ro following a court's dismissal of a lawsuit challenging the FDA's determination Wegovy ...

From a fundamental standpoint, Eli Lilly presently has a market capitalization of $789 billion. Over the trailing twelve ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Hims & Hers stock surges after Novo Nordisk announces Wegovy will be offered through telehealth platforms as shortages ease ...

On Friday, Mad Money host Jim Cramer took a close look at what he called one of the most important stretches of the earnings ...

Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies ...

Novo Nordisk said on Tuesday it was partnering with telehealth firms Hims & Hers , Ro and LifeMD to sell branded versions of ...